Astellas confirms plans to invest $257mn to develop R&D facilities in Japan and US

By Sean Galea-Pace
The Japan-based pharmaceutical company, Astellas Pharma, has announced it plans to invest $257mn to develop new R&D manufacturing facilities in thre...

The Japan-based pharmaceutical company, Astellas Pharma, has announced it plans to invest $257mn to develop new R&D manufacturing facilities in three sites in Japan and the US, BioPharmaDive reports.

It has been revealed that Astellas will create two centres in Japan, Toyama and Tsukuba, with both anticipated to be completed in 2019, in addition to one in Massachusetts, which is expected to reach completion in January 2020.

The new facility in Tsukuba is thought to cost around $44mn and will have the capability to develop clinical trial materials that can be utilised for Phase 1 and Phase 2 studies of cell and gene therapies in Japan, the US and Europe.  

See more:

In Toyama, Astellas are expected to invest almost $90mn to develop an 8,000 square-metre facility to create antibodies for both clinical and commercial uses.

However, the largest development is set to take place in the US with a new location of 24,000 square metres of its Institute for Regenerative Medicine.

The news follows Astellas recent movements in the last few years which has seen the company complete three deals to purchase assets in gene therapy, women’s health and mitochondrial research.

Share

Featured Articles

India’s smart manufacturing electric vehicle future

Indian IT service Panache Digilife has announced a manufacturing and supply chain agreement with electric vehicle manufacturer Revamp Moto

Manufacturing a legacy of safety, sustainability, and skill

Michael Vale, Group President for 3M’s safety & industrial business, explores diversity & environmental stewardship in manufacturing

5 minutes with: Simon Michie, Pulsant CTO

Simon Michie, CTO at Pulsant, explains why edge computing will transform manufacturing operations, but success will depend on having partnerships in place

Microsoft’s Çağlayan Arkan explores the supply chain

Procurement & Supply Chain

Elisabeth Brinton on the Microsoft Cloud for Sustainability

Technology

Aiimi’s Head of Solution Engineering Matt Eustace on risks

AI & Automation